Pivekimab
Modify Date: 2024-01-11 11:30:07
Pivekimab structure
|
Common Name | Pivekimab | ||
|---|---|---|---|---|
| CAS Number | 2234335-84-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PivekimabPivekimab is a human monoclonal IgG1 antibody targeting interleukin 3 (IL-3). Pivekimab is a CD123-targeting antibody-drug conjugate. Pivekimab can be used in research of blastic plasmacytoid dendritic cell neoplasm (BPDCN)[1]. |
| Name | Pivekimab |
|---|
| Description | Pivekimab is a human monoclonal IgG1 antibody targeting interleukin 3 (IL-3). Pivekimab is a CD123-targeting antibody-drug conjugate. Pivekimab can be used in research of blastic plasmacytoid dendritic cell neoplasm (BPDCN)[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Patrick ZM, et, al. Methods of treatment using anti-CD123 immunoconjugates. WO2020092533. |
| No Any Chemical & Physical Properties |